IGFBP2 and gastric cancer: The levels of IGFBP2 determined by RPPA were also increased in gastric cancer, cholangiocarcinoma, hepatocellular carcinoma, and colon cancer compared to healthy controls (S5 Fig), which corresponded to the result of LC-MS/MS.